By making intelligent connections, we bring innovation to the needs of today’s oncology development to help you focus on the patient, manage trial complexity, and increase predictability and speed. IQVIA helps you
Oncology drug development is shifting from a drug-centered approach to a patient-centered one. In the realm of oncology therapeutics, from dose escalation through dose optimization, IQVIA’s teams are here to help you navigate the evolving landscape and make informed decisions quickly.
Regulatory approvals (FDA, PMDA, MHRA, EC) across 14 indications in oncology from 2020 - 2023
Of FDA approved oncology drugs between 2016 – 2024 involved IQVIA
Of FDA approved hematology drugs between 2016 – 2024 involved IQVIA
Therapeutically aligned solutions to advance your clinical program to the next milestone.
Access new resources for advanced therapy development, from candidate identification through market authorization.
Predict enrollment more accurately and increase the number of patients per site using data-driven patient recruitment solutions.
Identify the best performing sites for your trial in less time with new machine learning and predictive modeling methods.
Access central labs around the globe through IQVIA Laboratories Solutions, a wholly owned subsidiary of IQVIA.
Unravel the complexities of cancer treatment with patient-level data-driven solutions.
Change the model of clinical research by integrating data, expertise, analytics and technology from study design through execution to power better decisions.
Access a dedicated network of European cancer hospitals to capture real world data that reflects the latest clinical practice and perform oncology studies faster.
.svg){kind=icon}
